Azelaic Acid for Central Centrifugal Cicatricial Alopecia
((CCCA) Trial)
Trial Summary
What is the purpose of this trial?
This trial is testing azelaic acid to see if it can help people with Central Centrifugal Cicatricial Alopecia (CCCA), a challenging hair loss condition. Azelaic acid might reduce inflammation, which could help hair grow back. The study aims to determine the effectiveness of azelaic acid. Azelaic acid has been used effectively for treating acne and rosacea, and it has shown potential in promoting hair growth when combined with minoxidil.
Will I have to stop taking my current medications?
The trial requires that participants have been on a stable treatment without changes for at least three months, so you should not stop taking your current medications if they have been stable.
What evidence supports the effectiveness of the drug azelaic acid for treating central centrifugal cicatricial alopecia?
How does the drug azelaic acid differ from other treatments for central centrifugal cicatricial alopecia?
Azelaic acid is unique because it has antimicrobial and anti-inflammatory properties, and it normalizes keratinization (the process of forming the outer layer of skin), which may help in conditions like central centrifugal cicatricial alopecia. Unlike some other treatments, it is less irritating and does not cause allergic reactions, making it suitable for long-term use.12678
Research Team
Amy McMichael, MD
Principal Investigator
Wake Forest University Health Sciences
Eligibility Criteria
This trial is for women over 18 with a confirmed diagnosis of Central Centrifugal Cicatricial Alopecia (CCCA) stages II-IV. Participants must have been on a stable treatment plan for at least three months without changes, and they are recruited from outpatient dermatology clinics.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive azelaic acid or placebo treatment applied topically on the scalp once daily
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Azelaic Acid (Other)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Wake Forest University Health Sciences
Lead Sponsor
Dr. L. Ebony Boulware
Wake Forest University Health Sciences
Chief Medical Officer since 2022
MD from Duke University School of Medicine, MPH from Johns Hopkins Bloomberg School of Public Health
Dr. Julie Ann Freischlag
Wake Forest University Health Sciences
Chief Executive Officer since 2020
BS from University of Illinois, MD from Rush University